NO960743L - Cellulære preparater, deres fremstilling og terapeutiske anvendelse - Google Patents

Cellulære preparater, deres fremstilling og terapeutiske anvendelse

Info

Publication number
NO960743L
NO960743L NO960743A NO960743A NO960743L NO 960743 L NO960743 L NO 960743L NO 960743 A NO960743 A NO 960743A NO 960743 A NO960743 A NO 960743A NO 960743 L NO960743 L NO 960743L
Authority
NO
Norway
Prior art keywords
preparation
therapeutic use
cellular preparations
preparations
cellular
Prior art date
Application number
NO960743A
Other languages
English (en)
Other versions
NO960743D0 (no
NO319990B1 (no
Inventor
Hedi Haddada
Manuel Lopez
Michel Perricaudet
Original Assignee
Rhone Poulenc Rorer Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa, Inst Nat Sante Rech Med filed Critical Rhone Poulenc Rorer Sa
Publication of NO960743D0 publication Critical patent/NO960743D0/no
Publication of NO960743L publication Critical patent/NO960743L/no
Publication of NO319990B1 publication Critical patent/NO319990B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19960743A 1993-08-25 1996-02-23 Cellulaere preparater, forloper-celler for monocyttmakrofager, farmasoytisk preparat og deres fremstilling. NO319990B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9310222A FR2709309B1 (fr) 1993-08-25 1993-08-25 Compositions cellulaires, préparation et utilisations thérapeutiques.
PCT/FR1994/001019 WO1995006120A1 (fr) 1993-08-25 1994-08-22 Cellules recombinantes de la lignee monocyte-macrophage pour la therapie genique

Publications (3)

Publication Number Publication Date
NO960743D0 NO960743D0 (no) 1996-02-23
NO960743L true NO960743L (no) 1996-03-25
NO319990B1 NO319990B1 (no) 2005-10-10

Family

ID=9450378

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19960743A NO319990B1 (no) 1993-08-25 1996-02-23 Cellulaere preparater, forloper-celler for monocyttmakrofager, farmasoytisk preparat og deres fremstilling.

Country Status (14)

Country Link
US (1) US6210963B1 (no)
EP (1) EP0719332B1 (no)
JP (1) JP3731035B2 (no)
KR (1) KR100392984B1 (no)
AT (1) ATE272117T1 (no)
AU (1) AU698043B2 (no)
CA (1) CA2170159A1 (no)
DE (1) DE69433921T2 (no)
FI (1) FI960855A (no)
FR (1) FR2709309B1 (no)
IL (1) IL110754A (no)
NO (1) NO319990B1 (no)
WO (1) WO1995006120A1 (no)
ZA (1) ZA946264B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029183A2 (en) * 1996-02-08 1997-08-14 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating t cells
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
GB2332434B (en) * 1996-10-09 2001-04-04 Oxford Biomedica Ltd Mononuclear phagocytes in therapeutic drug delivery
US20020068048A1 (en) * 1997-09-05 2002-06-06 Patrick A. Dreyfus Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues
WO1999015684A2 (en) * 1997-09-23 1999-04-01 Oxford Biomedica (Uk) Limited Expression of genes in hematopoietic stem cells in hischaemic conditions
WO2000060054A1 (en) * 1999-04-06 2000-10-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pharmaceutical compositions comprising circulating blood cells, preferably monocytes and uses thereof
WO2001087314A1 (en) * 2000-05-18 2001-11-22 Genetix Pharmaceuticals, Inc. Methods and compositions for promoting angiogenesis using monocytes
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
US20030175242A1 (en) * 2001-09-17 2003-09-18 Micheal Gruenberg Cell therapy system
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
CA2425021A1 (en) * 2002-04-12 2003-10-12 Sumitomo Electric Industries, Ltd. Control of the ratio of lap to lip
RU2377253C2 (ru) * 2002-12-02 2009-12-27 Амген Фремонт,Инк. Антитела, специфичные к фактору некроза опухолей, и их применение
WO2004073624A2 (en) 2003-02-14 2004-09-02 The Curators Of The University Of Missouri Contraceptive methods and compositions related to proteasomal interference
CN1957084A (zh) * 2004-03-23 2007-05-02 株式会社载体研究所 与组织的维持和/或修复相关联的骨髓相关细胞
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
NZ575571A (en) * 2006-10-04 2011-11-25 Janssen Pharmaceutica Nv Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
ES2560432T3 (es) * 2007-01-12 2016-02-19 The Board Of Trustees Of The University Of Illinois Células no símicas para el desarrollo del virus del síndrome reproductivo y respiratorio porcino (PRRS)
JP5546107B2 (ja) * 2008-04-17 2014-07-09 国立大学法人宇都宮大学 ＲＮＡウイルスＢｍＭＬＶ陰性カイコ培養細胞株
EP2248903A1 (en) * 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
KR102502974B1 (ko) 2013-04-18 2023-02-23 틸트 바이오세러퓨틱스 오이 향상된 입양 세포 치료
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CA3058434A1 (en) * 2017-03-28 2018-10-04 Zhenglun Zhu Methods of treating neoplastic diseases
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
KR20220097875A (ko) 2019-09-03 2022-07-08 마이얼로이드 테라퓨틱스, 인크. 게놈 통합을 위한 방법 및 조성물
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
WO2022098905A2 (en) 2020-11-04 2022-05-12 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
CA3212398A1 (en) 2021-03-17 2022-09-22 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof
CN114657143B (zh) * 2022-03-11 2022-10-25 西安电子科技大学 一种肿瘤微环境调控型car-单核/巨噬细胞及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005349A1 (en) * 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
CA1340565C (en) * 1989-06-29 1999-05-25 Thomas B. Okarma Device and process for cell capture and recovery
US5246921A (en) * 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
FR2683725B1 (fr) * 1991-11-15 1995-07-07 Pasteur Institut Composition cellulaire pour le traitement des organismes humains ou animaux.
AU673987C (en) * 1991-11-22 2005-02-17 General Hospital Corporation, The Specific tolerance in transplantation
US5338165A (en) * 1991-11-25 1994-08-16 Ford Motor Company Automotive fuel pump with modular pump housing
GB9125623D0 (en) * 1991-12-02 1992-01-29 Dynal As Cell modification
US5436151A (en) * 1992-04-03 1995-07-25 Regents Of The University Of Minnesota Method for culturing human hematopoietic stem cells in vitro
DE4219626A1 (de) * 1992-06-16 1993-12-23 Wehling Peter Priv Doz Dr Med Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen
WO1994021680A1 (en) * 1993-03-17 1994-09-29 The Government Of The United States Of America As Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
WO1996025507A2 (en) * 1995-02-17 1996-08-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of preparation and use of recombinant adenoviral vectors

Also Published As

Publication number Publication date
ATE272117T1 (de) 2004-08-15
NO960743D0 (no) 1996-02-23
FI960855A (fi) 1996-04-23
EP0719332A1 (fr) 1996-07-03
JP3731035B2 (ja) 2006-01-05
FR2709309A1 (fr) 1995-03-03
AU7539894A (en) 1995-03-21
CA2170159A1 (fr) 1995-03-02
WO1995006120A1 (fr) 1995-03-02
JPH09501837A (ja) 1997-02-25
KR100392984B1 (ko) 2004-10-20
IL110754A0 (en) 1994-11-11
IL110754A (en) 2001-04-30
FI960855A0 (fi) 1996-02-23
FR2709309B1 (fr) 1995-11-10
NO319990B1 (no) 2005-10-10
EP0719332B1 (fr) 2004-07-28
DE69433921D1 (de) 2004-09-02
DE69433921T2 (de) 2006-10-05
US6210963B1 (en) 2001-04-03
ZA946264B (en) 1995-03-20
AU698043B2 (en) 1998-10-22

Similar Documents

Publication Publication Date Title
NO960743D0 (no) Cellulære preparater, deres fremstilling og terapeutiske anvendelse
NO950939L (no) Defektive adenovirusvektorer og deres anvendelse i gene-terapien
AU6753394A (en) Determination of lymph nodes enriched in tumor reactive cells, their proliferation, and their use in adoptive cellular therapy
FI962154A (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
EP0959889A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING PROLIFERATION OF KERATINOCYTE
BR0010563A (pt) Composições isoladas de células da pele e métodos para seu uso
GB9825096D0 (en) Cells,culture methods and their uses
AU5168099A (en) Use of novel agents inducing cell death in synergy with interferons
ES2144626T3 (es) Uso de peptidos de adhesion celular para la modificacion del poder de adhesion de celulas eucarioticas entre si.
EP0160486A3 (en) Monoclonal antibodies
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
GB2379446A (en) Cells,culture methods and their uses
MY131599A (en) Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity
DK0925064T3 (da) 5-Androsten-3-beta,17-alpha-diol som inhibitor for tumorvækst
AU7357894A (en) Native-state method and system for determining viability and proliferative capacity of tissues (in vitro)
MX9602765A (es) Celulas secretorias macroencapsuladas.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees